NVDA 162.85 ▼2.01%GOOGL 295.77 ▼0.98%MSFT 523.88 ▲0.17%AMD 534.06 ▼8.75%INTC 59.66 ▼2.52%TSMC 398.73 ▼1.67%AMZN 266.66 ▼0.29%META 641.69 ▲2.90%AAPL 356.27 ▲0.39%PLTR 167.99 ▼2.09%
Markets at last close

Health

Manas AI shortens early cancer drug discovery timelines

·1 min read

Manas AI is compressing early-stage cancer drug discovery from nearly eight years to three or four months, according to co-founder and CEO Dr. Siddhartha Mukherjee. Speaking at the Hindustan Times Leadership Summit in New Delhi, he described an approach that combines machine learning with physics and chemistry to identify vulnerabilities in disease-causing proteins and design molecules to block them.

The company pairs molecular design with automated robotic laboratory testing, completing each design-and-test cycle in three weeks. Mukherjee said its algorithms identified a target spot on a pancreatic cancer protein in two hours, a task that previously took researchers a decade. He also reported experimental cancer candidates up to 200 times stronger than existing competitor drugs, though these remain early-stage findings rather than evidence of successful human treatment.

Mukherjee cautioned that biologically distinct cancers cannot be addressed with a universal cure. Human clinical trials, manufacturing and government approvals still take years and contribute substantially to costs. He urged India and China to streamline testing rules without compromising safety.

He also highlighted Immuneel Therapeutics, the Bengaluru-based cell therapy company he co-founded with Kiran Mazumdar-Shaw. Using hospital-adjacent automated manufacturing and AI-designed binders, the company developed customized blood cancer treatments costing roughly $35,000 in India compared with $500,000 in the United States, he said.

Originally reported by menafn.comRead the source →
Related coverage